FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL)

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Kabir, Nuzhat N ^a   Rönnstrand, Lars ^b   Kazi, Julhash U ^a,b  

^a KN Biomedical Research Institute   (Bangladesh)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE FLT3; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CHILDHOOD LEUKEMIA; GENE MUTATION; HEMATOPOIESIS; HUMAN; LETTER; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CHILD; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; MALE; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84872275540     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0462-6     Document Type: Letter

References (3)

1. Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103:3544-6.
2. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-42.
3. Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R, Tsuchida M, Sugita K, Ida K, Hayashi Y. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103:1085-8.